{"nctId":"NCT05134649","briefTitle":"A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","startDateStruct":{"date":"2021-11-16","type":"ACTUAL"},"conditions":["Platysma Prominence"],"count":292,"armGroups":[{"label":"BOTOX","type":"EXPERIMENTAL","interventionNames":["Drug: OnabotulinumtoxinA"]}],"interventions":[{"name":"OnabotulinumtoxinA","otherNames":["BOTOX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Completion of all phases of the lead-in Phase 3 study (Screening Period, Treatment Period \\[randomization/treatment with 4-month follow-up visit\\] and Study Exit visit)\n\nExclusion Criteria:\n\n* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function\n* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)\n* Anticipated need for surgery or overnight hospitalization during the study\n* Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study\n* Known immunization or hypersensitivity to any botulinum toxin serotype\n* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months\n* Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"111","spread":null},{"groupId":"OG006","value":"127","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":292},"commonTop":["COVID-19","INJECTION SITE BRUISING","NASOPHARYNGITIS"]}}}